文献速递泌尿男性生殖肿瘤

68Ga-PSMA-11 PET在生化复发前列腺癌定位中的准确性评估:一项前瞻性单臂临床试验

Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
PubMed 文献 · JAMA Oncol · 2019-01-01

这项前瞻性单臂多中心试验在635例生化复发前列腺癌患者中评估68Ga-PSMA-11 PET的定位准确性。结果显示,基于组织病理学验证的阳性预测值为0.84(95%CI 0.75-0.90),复合参考标准为0.92(95%CI 0.88-0.95);总体检出率为75%,且检出率随PSA水平升高而显著增加(P<.001)。

要点

  • 68Ga-PSMA-11 PET在生化复发前列腺癌中检出率为75%(475/635)。
  • 基于组织病理学验证的阳性预测值为0.84(95%CI 0.75-0.90,n=87)。
  • 检出率随PSA升高而增加:<0.5 ng/mL为38%,≥5.0 ng/mL为97%(P<.001)。

核心结论

  • 采用盲法判读和独立病灶验证,68Ga-PSMA-11 PET在生化复发前列腺癌定位中显示出高阳性预测值、检出率和判读者间一致性。

研究设计与样本

  • 前瞻性单臂临床试验,在加州大学旧金山分校和加州大学洛杉矶分校开展。
  • 共纳入635例前列腺癌根治术后(n=262,41%)、放疗后(n=169,27%)或两者兼有(n=204,32%)的生化复发患者,接受68Ga-PSMA-11 PET检查。
  • 由3名盲法判读者按患者水平和区域水平记录前列腺癌存在情况,病灶通过组织病理学分析和复合参考标准进行验证。

主要发现

  • 按患者分析,基于组织病理学验证的阳性预测值为0.84(95%CI 0.75-0.90,主要终点,n=87),基于复合参考标准的阳性预测值为0.92(95%CI 0.88-0.95,n=217)。
  • 68Ga-PSMA-11 PET在475/635(75%)例患者中定位了复发前列腺癌。
  • 检出率随PSA水平升高而显著增加:PSA<0.5 ng/mL为38%(n=136),0.5至<1.0 ng/mL为57%(n=79),1.0至<2.0 ng/mL为84%(n=89),2.0至<5.0 ng/mL为86%(n=158),≥5.0 ng/mL为97%(n=173),P<.001。
  • 判读者间可重复性为中等至高度一致(Fleiss κ,0.65-0.78)。
  • 未发生与68Ga-PSMA-11给药相关的严重不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In retrospective studies, 68Ga-PSMA-11 positron emission tomographic (PET) imaging improves detection of biochemically recurrent prostate cancer compared with conventional imaging. OBJECTIVE: To assess 68Ga-PSMA-11 PET accuracy in a prospective multicenter trial. DESIGN, SETTING, AND PARTICIPANTS: In this single-arm prospective trial conducted at University of California, San Francisco and University of California, Los Angeles, 635 patients with biochemically recurrent prostate cancer after prostatectomy (n = 262, 41%), radiation therapy (n = 169, 27%), or both (n = 204, 32%) underwent 68Ga-PSMA-11 PET. Presence of prostate cancer was recorded by 3 blinded readers on a per-patient and per-region base. Lesions were validated by histopathologic analysis and a composite reference standard. MAIN OUTCOMES AND MEASURES: Endpoints were positive predictive value (PPV), detection rate, interreader reproducibility, and safety. RESULTS: A total of 635 men were enrolled with a median age of 69 years (range, 44-95 years). On a per-patient basis, PPV was 0.84 (95% CI, 0.75-0.90) by histopathologic validation (primary endpoint, n = 87) and 0.92 (95% CI, 0.88-0.95) by the composite reference standard (n = 217). 68Ga-PSMA-11 PET localized recurrent prostate cancer in 475 of 635 (75%) patients; detection rates significantly increased with prostate-specific antigen (PSA): 38% for <0.5 ng/mL (n = 136), 57% for 0.5 to <1.0 ng/mL (n = 79), 84% for 1.0 to <2.0 ng/mL (n = 89), 86% for 2.0 to <5.0 ng/mL (n = 158), and 97% for ≥5.0 ng/mL (n = 173, P < .001). Interreader reproducibility was substantial (Fleiss κ, 0.65-0.78). There were no serious adverse events associated with 68Ga-PSMA-11 administration. PET-directed focal therapy alone led to a PSA drop of 50% or more in 31 of 39 (80%) patients. CONCLUSIONS AND RELEVANCE: Using blinded reads and independent lesion validation, we establish high PPV for 68Ga-PSMA-11 PET, detection rate and interreader agreement for localization of recurrent prostate cancer. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT02940262 and NCT03353740.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019. PMID: 30920593. doi:10.1001/jamaoncol.2019.0096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。